David Parry

David Parry joined Samsara Biocapital in 2021. From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space. Following DNAX he joined Portola Pharmaceuticals, working on inflammatory disease and oncology drug discovery/development. After Portola, David joined the Discovery Partnerships with Academia (DPAc) Research Unit at GSK. Within DPAc he worked extensively with multiple US/EU academic institutions to identify and progress early-stage innovation utilizing the capabilities of pharma within a collaborative, milestone-based framework. During the last two years, he worked within the Global BD organization at GSK focusing on search, evaluation and due diligence of immunology-focused opportunities. David received his B.Sc. (Hons) in Biochemistry from The University of Manchester Institute of Science and Technology (UMIST) and a Ph.D. in Molecular Oncology from The Imperial Cancer Research Fund (ICRF).